These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34190621)
1. Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis. Abeldaño Zuñiga RA; González-Villoria RAM; Elizondo MV; Osorio AYN; Martínez DG; Coca SM Ther Adv Respir Dis; 2021; 15():17534666211028077. PubMed ID: 34190621 [TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969 [TBL] [Abstract][Full Text] [Related]
3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959 [TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
6. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Janiaud P; Axfors C; Schmitt AM; Gloy V; Ebrahimi F; Hepprich M; Smith ER; Haber NA; Khanna N; Moher D; Goodman SN; Ioannidis JPA; Hemkens LG JAMA; 2021 Mar; 325(12):1185-1195. PubMed ID: 33635310 [TBL] [Abstract][Full Text] [Related]
7. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
8. Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression. Snow TAC; Saleem N; Ambler G; Nastouli E; McCoy LE; Singer M; Arulkumaran N Br J Anaesth; 2021 Dec; 127(6):834-844. PubMed ID: 34579942 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747 [TBL] [Abstract][Full Text] [Related]
11. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114 [TBL] [Abstract][Full Text] [Related]
12. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499 [TBL] [Abstract][Full Text] [Related]
13. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Ling RR; Sim JJL; Tan FL; Tai BC; Syn N; Mucheli SS; Fan BE; Mitra S; Ramanathan K Transfus Med Rev; 2022 Jan; 36(1):16-26. PubMed ID: 34782209 [TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257 [TBL] [Abstract][Full Text] [Related]